Search - tctmd.com

Displaying 81 - 100 of 146

Sort: Relevancy | Date

Presentation TCT 2017

Taped and Edited Live-Case of the Use of a TriGuard Cerebral Protection Device During TAVR With Sapien 3

Presenter: Francesco Saia, Gerhard C. Schuler, Pieter R. Stella

October 31, 2017

Presentation TCT 2017

Impella and Rotablation-assisted Bifurcation PCI Following Previous Edwards SAPIEN 3 TAVR

Presenter: Mohamed Ahmed Sobhy, Faisal Khan

October 30, 2017

Presentation TCT 2017

Percutaneous Mitral Valve-in Valve Implantation With SAPIEN 3 Prosthesis Using an Anterograde Transvenous Transseptal Approach

Presenter: Vasilis Babaliaros, Shmuel Banai, Caterina Gandolfo

October 30, 2017

Presentation TCT 2017

Case #8: Transseptal Mitral ViMAC With SAPIEN 3 (With Discussion)

Presenter: Mayra Guerrero, Nicolas M. Van Mieghem

October 30, 2017

Presentation TCT 2017

Case #4: Trans-septal Mitral ViV With SAPIEN 3 (With Discussion)

Presenter: Mayra Guerrero, Nicolas M. Van Mieghem, Mackram F. Eleid

October 30, 2017

Presentation TCT 2017

Case #2: TAVR ViV With SAPIEN 3 (With Discussion)

Presenter: Mayra Guerrero, Nicolas M. Van Mieghem, Anupama Shivaraju

October 30, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Todd Neale

November 01, 2016

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

News Conference News TCT 2016

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Todd Neale

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Presentation TCT 2016

TCT 1524: Simultaneous Transfemoral Aortic and Transseptal Mitral Valves Replacement Utilizing Sapien 3 Valves in Native Aortic and Mitral Valves

Presenter: David R. Holmes Jr., Clifford J. Kavinsky, Firas Zahr

October 31, 2016

Presentation TCT 2016

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Presenter: Neil E. Moat, John G. Webb, Pieter R. Stella

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

TCT 38: Paravalvular Regurgitation Regression and Impact on One-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Transcatheter Valve

Presenter: Lutz Buellesfeld, Raj Makkar, Philippe Pibarot

October 31, 2016

Title Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presentation TCT 2016

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Suzanne Baron

October 31, 2016

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

Combined Single-Session Tavi With Edwards Sapien 3 Aortic Valve and Percutaneous Closure of the Left Atrial Appendage in a Elderly Comorbid Patient

Presenter: Maurice Buchbinder, Horst Sievert, Caterina Gandolfo

October 31, 2016

Advertisement

Taped and Edited Live-Case of the Use of a TriGuard Cerebral Protection Device During TAVR With Sapien 3

Impella and Rotablation-assisted Bifurcation PCI Following Previous Edwards SAPIEN 3 TAVR

Percutaneous Mitral Valve-in Valve Implantation With SAPIEN 3 Prosthesis Using an Anterograde Transvenous Transseptal Approach

Case #8: Transseptal Mitral ViMAC With SAPIEN 3 (With Discussion)

Case #4: Trans-septal Mitral ViV With SAPIEN 3 (With Discussion)

Case #2: TAVR ViV With SAPIEN 3 (With Discussion)

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

TCT 1524: Simultaneous Transfemoral Aortic and Transseptal Mitral Valves Replacement Utilizing Sapien 3 Valves in Native Aortic and Mitral Valves

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

TCT 38: Paravalvular Regurgitation Regression and Impact on One-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Transcatheter Valve

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Combined Single-Session Tavi With Edwards Sapien 3 Aortic Valve and Percutaneous Closure of the Left Atrial Appendage in a Elderly Comorbid Patient

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content